Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 15 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2017 Filed Jun 15, 2017 16:41 UTC |
Hudson Frederick M.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-17-039590 · a4.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,036 Underlying: Common Stock · 6,036 shares Expires 2027-06-13 Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 16:43 UTC |
SIEBERT JOHN MDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-17-039594 · a4.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,036 Underlying: Common Stock · 6,036 shares Expires 2027-06-13 Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:41 UTC |
GEMAYEL GEORGESDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-17-039589 · a4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,036 Underlying: Common Stock · 6,036 shares Expires 2027-06-13 Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:42 UTC |
Nuerge William A.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-17-039593 · a4.xml · derivative · entry 2 Nuerge William A. · CIK 0001540039 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,036 Underlying: Common Stock · 6,036 shares Expires 2027-06-13 Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 22:19 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 10,000 | $39.86 | $398,558.00 |
DisclosureSEC source: 0001104659-17-037540 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.8500 to $39.9300, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 26, 2017 Filed May 31, 2017 00:58 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 2,500 | $35.90 | $89,757.50 |
DisclosureSEC source: 0001104659-17-036322 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9000 to $35.9250, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 25, 2017 Filed May 25, 2017 23:08 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 3,887 | $34.90 | $135,656.30 |
DisclosureSEC source: 0001104659-17-035312 · a4.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. Read SEC document |
| May 24, 2017 Filed May 25, 2017 23:08 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 1,613 | $34.90 | $56,293.70 |
DisclosureSEC source: 0001104659-17-035312 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,887 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. Read SEC document |
| April 24, 2017 Filed Apr 24, 2017 20:47 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 11,806 | $32.59 | $384,762.26 |
DisclosureSEC source: 0001104659-17-025476 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.3250 to $32.6750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 16:17 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001104659-17-026371 · a4.xml · derivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 50,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 22, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 16:17 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
SaleCommon Stock | 54,000 | $32.37 | $1,747,872.00 |
DisclosureSEC source: 0001104659-17-026371 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 22, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.2500 to $32.7500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 16:17 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 50,000 | $5.88 | $294,000.00 |
DisclosureSEC source: 0001104659-17-026371 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 22, 2017. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 20:57 UTC |
Khattar Jack A.Director · President, CEO
|
OtherCommon Stock | 4,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-021402 · a4.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the KBT Trust Disclosed balance after: 1,089,750 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 4,250 shares were transferred from the KBT Trust to the Reporting Person on April 3, 2017 without consideration and are now owned directly. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 20:57 UTC |
Khattar Jack A.Director · President, CEO
|
OtherCommon Stock | 4,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-021402 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,909 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 4,250 shares were transferred from the KBT Trust to the Reporting Person on April 3, 2017 without consideration and are now owned directly. F1 · balance_after: The Reporting Person is filing this Form 4 to reflect the fact that 4,250 shares were transferred from the KBT Trust to the Reporting Person on April 3, 2017 without consideration and are now owned directly. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:57 UTC |
NEWHALL CHARLES W IIIDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012173 · a4.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:55 UTC |
Hudson Frederick M.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012170 · a4.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:56 UTC |
SIEBERT JOHN MDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012171 · a4.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:58 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012175 · a4.xml · derivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-24 F2 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 02:56 UTC |
GEMAYEL GEORGESDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012172 · a4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 02:59 UTC |
Schwabe Stefan K.F.Executive Vice President R&D
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012179 · a4.xml · derivative · entry 2 Schwabe Stefan K.F. · CIK 0001557657 · Executive Vice President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-24 F2 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 02:59 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012178 · a4.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-02-24 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 24, 2018. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 02:58 UTC |
Vaughn VictorSr. VP of Sales
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012177 · a4.xml · derivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-24 F2 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 02:57 UTC |
Khattar Jack A.Director · President, CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012174 · a4.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2027-02-24 F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 02:55 UTC |
Nuerge William A.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012169 · a4.xml · derivative · entry 2 Nuerge William A. · CIK 0001540039 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Read SEC document |
| September 16, 2016 Filed Sep 16, 2016 17:10 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
SaleCommon Stock | 2,000 | $25.00 | $50,000.00 |
DisclosureSEC source: 0001104659-16-145199 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,616 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted on March 24, 2015, as amended May 9, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.